Lipichol

Atorvastatin, the active ingredient in Lipichol, is a HMG‑CoA reductase inhibitor presented as an oral tablet for systemic use. It lowers elevated cholesterol levels and is prescribed to reduce cardiovascular risk in adults with hypercholesterolemia.

GNH USA supplies Lipichol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for this lipid‑lowering agent. Customers benefit from consistent batch release, comprehensive documentation, and responsive technical support throughout the supply chain.

Atorvastatin is used to manage disorders of lipid metabolism and to reduce cardiovascular risk.

- Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. - Primary prevention of cardiovascular disease: lowers the risk of myocardial infarction, stroke and related events. - Familial hypercholesterolemia: improves lipid profile in patients with genetically elevated cholesterol. - Mixed dyslipidemia: decreases triglycerides and raises HDL‑cholesterol modestly. - Secondary prevention after myocardial infarction: helps maintain target lipid levels. - Post‑coronary revascularization: supports long‑term lipid control to prevent graft occlusion.

Atorvastatin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Muscle aches or weakness - Headache - Nausea

Serious or Rare Side Effects: - Rhabdomyolysis with renal impairment - Severe liver injury - Life‑threatening allergic reactions (e.g., anaphylaxis)

When prescribing atorvastatin, clinicians should consider several precautionary measures to ensure patient safety.

- Baseline liver assessment: obtain hepatic function tests before initiating therapy and monitor periodically. - Renal function evaluation: adjust use in patients with severe renal impairment. - Drug interaction review: avoid concomitant use with strong CYP3A4 inhibitors. - Pregnancy and lactation: contraindicated in pregnancy; assess risks in breastfeeding. - Muscle symptom monitoring: educate patients to report unexplained muscle pain or weakness promptly. - Store at room temperature: keep tablets in the original container, protect from moisture and light.

Atorvastatin interacts with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ritonavir) – may markedly increase atorvastatin exposure. - Gemfibrozil – increases risk of myopathy and rhabdomyolysis. - Cyclosporine – elevates plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Antacids (e.g., aluminum hydroxide) – may reduce absorption, monitor lipid levels. - Warfarin – may enhance anticoagulant effect, check INR regularly. - Digoxin – possible increase in serum levels, monitor for toxicity.